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Abstract
The use of poly(lactic-co-glycolic acid) (PLGA)-based nanocarriers presents several major challenges, including their
synthetic hydrophobic surface, low transfection efficiency, short circulation half-life, and nonspecific tissue
distribution. Numerous engineering strategies have been employed to overcome these problems, with lipid-based
surface functionalization of PLGA nanoparticles (NPs) showing promising results in the development of PLGA-based
clinical nanomedicines. Surface engineering with different lipids enhances the target specificity of the carrier and
improves its physicochemical properties as well as NP-cell associations, such as cellular membrane permeability,
immune responses, and long circulation half-life in vivo. This review focuses on recent advances in the lipid-based
surface engineering of PLGA NPs for drug and gene delivery applications.
Keywords: Surface engineering, Lipids, PLGA nanoparticle, Self assembly, Cell membrane derived lipid vesicles,
Biomimetic fucntionalization, Controlled drug release, Gene delivery
Background
Nanotechnology has been widely studied to improve the
pharmacokinetics and therapeutic efficacy of a myriad of
drugs, including proteins, genes, and other small mole-
cules [1–4]. In recent years, several therapeutics based
on poly(lactic-co-glycolic acid) (PLGA) nanoparticles
(NPs) (hereinafter abbreviated PNPs) have entered into
preclinical development or are being investigated in bio-
medical research, owing to their attractive properties of
biodegradability, biocompatibility, ease of processing,
and sustained release [5–8]. To optimize their clinical
potential, considerable efforts have been devoted to un-
derstanding the mechanism of interaction between the
PNP surface and its biological environment [9]. The
major barrier to the use of the PNP is its hydrophobic
surface, which is often recognized as foreign material by
immune cells, leading to its rapid elimination from sys-
temic circulation [10]. In addition, this surface property
of the PNP limits its cellular membrane permeability,
often resulting in poor transfection efficiency in in vitro
experiments [11]. To address these limitations, numerous
strategies have been investigated [9–14], among which
lipid-based surface engineering has been shown to be ef-
fective in preclinical studies owing to the biomimetic and
biocompatible advantages of this strategy [10, 12, 15]. Cur-
rently, a broad range of lipids have been determined to
significantly improve the therapeutic potential of the PNP
platform [13, 16, 17]. The present review focuses on re-
cent advances in the lipid-based surface engineering of
PNPs for drug and gene delivery applications. We provide
recent information regarding the surface engineering
methods based on synthetic lipids and on natural cell-
membrane-derived lipid vesicles (nanoghosts) [11, 15, 18,
19]. The methods used in lipid-based surface engineering,
and the properties and biomedical applications of the
lipid-PLGA hybrid nanoparticles (LPHNPs) produced, are
described in detail. Discussion of other types of surface
modification techniques is limited as these are not within
the scope of this review.
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Lipid-based surface engineering of PLGA
nanoparticles
Lipids are hydrophobic or amphiphilic molecules,
present in various molecular types such as fatty acids,
oils, steroids and waxes [20]. Among all, glyceropho-
spholipids are the main component of biological mem-
branes, which composed of a glycerol molecule linked to
a phosphate group (PO4
2−) and to two fatty acids [20].
These phospholipids have been widely employed for the
surface engineering of PNPs. Phospholipids such as
phosphatidylcholine, phosphatidylinositol, phosphatidyl-
glycerol, phosphatidylethanolamine, phosphatidylserine,
and phosphatidic acid are less stable in nature [21, 22].
Thus their synthetic counterparts have been synthesized
by modification of the nonpolar and polar regions of the
phospholipid molecules [21]. Differentially charged syn-
thetic phospholipids, such as zwitterionic, cationic, an-
ionic, and neutral phospholipids (e.g., DOTAP, and
sterol lipids such as cholesterol), are often used in bio-
medical engineering [13, 15]. Polyethylene glycol (PEG)
is a hydrophilic lipid that has been largely applied to im-
prove the circulation half-life of NPs in blood [17, 18,
23, 24]. The amphiphilic nature of phospholipids allows
them to form organized structures, such as vesicles or
membranes, when immersed in an aqueous environ-
ment. Additionally, lipid self-assembly on the polymeric
substrate depends on their surface properties, such as
charge and nature of substrate (hydrophilic/hydropho-
bic) [16]. In general, electrostatic attraction and hydro-
phobic interactions are the major chemical forces
responsible for the lipid self-assembly process on PNP
surfaces [17, 18]. The incorporation of anionic or cat-
ionic lipids into a phospholipid bilayer yields charged
vesicles that can be adsorbed onto oppositely charged
polymeric NPs via electrostatic attraction [13]. Neutral
phospholipids, such as phosphatidylcholine and dipalmi-
toylphosphatidylcholine, adsorb and self-assemble onto
hydrophobic polymeric surfaces through hydrophobic
interactions in order to reduce the free energy of the
system [15, 18]. The hydrophobic tails of lipids adsorb
onto the hydrophobic PNP surface, while the hydrophilic
head groups of the lipids extend into the external aque-
ous environment, forming a lipid-monolayer-coated PNP
imparting aqueous stability [15]. As more and more
lipids are added to the NP dispersion, vesicles form in
addition to lipid-monolayer-coated NPs [17, 18]. The lat-
ter can interact with the vesicles via van der Waals inter-
actions, resulting in further lipid deposition and thus
increasingly larger numbers of lipid monolayers onto the
PNPs [18].
Advantages in using synthetic lipids, such as DOTAP,
for surface engineering of PNPs include the ease of pro-
cessing and customization [13, 16]. However, adverse ef-
fects, such as the cytotoxicity of the PNPs produced and
the immune responses they elicit, have fueled new surface
engineering strategies, such as natural cell-membrane-
derived lipid vesicles (nanoghosts) [10, 12, 19, 25, 26]. The
motivation behind this new development lies in the fact
that natural cell membrane components (i.e., lipids, pro-
teins, and carbohydrates) have complex structures that are
difficult to mimic with synthetic lipids alone [19].
Researchers have investigated various natural cell-
membrane-derived nanoghosts from erythrocytes (RBCs),
leukocytes, platelets, stem cells, and cancer cells for the
surface engineering of PNPs [10, 12, 14, 19, 25, 26]. This
cell membrane functionalized nanoparticles (CMFNPs)
have the combined advantages of both cell mimetic sur-
face and polymeric NPs [26, 27]. The lipid and protein
compositions of these nanoghosts offer the unique advan-
tage of source cell surface to the PNPs [27]. For instance,
RBC-derived nanoghosts enable the PNPs to have ex-
tended the circulation half-life in vivo [10].
Methods in lipid-based surface engineering of
PLGA nanoparticles
There are many methods employed for the lipid-based
surface engineering of PNPs [17, 19, 28, 29]. Fig. 1 de-
picts different methods for fabrication of lipid-PNPs.
Fabrication using synthetic lipids can be achieved by ei-
ther the classical two-step method or the contemporary
single-step process [17, 18]. The selection of right
method of preparation is depends on various factors
such as size, shape and nature of drug incorporation
with the engineered nanoparticles. In the classical two-
step method, the preformed PNPs are mixed with pre-
formed lipid vesicles, where the latter adsorb onto the
polymeric NPs by electrostatic interactions [30]. Non-
conventional soft lithography and spray drying methods
are also applied to create PNPs of different sizes and
shapes [31]. Top-down methods have been generally
employed for the nanoghost-based surface engineering
of PNPs, the major steps of which (including separation
of cell membranes and surface engineering methods)
have been briefly discussed in our recent review [19].
The nanoprecipitation and emulsification-solvent-
evaporation (ESE) techniques can be customized for PNP
preparation by the single-step method [13, 15, 16, 32]. In
the single-step nanoprecipitation method, where the
PLGA polymer and the lipids are either dissolved in
organic solvent or the lipid and/or the lipid-PEG are
dispersed in water. The PLGA polymer solution is then
dropped into an aqueous phase under constant stirring,
causing the precipitation of PNPs [13, 16]. During solvent
evaporation, the lipids self-assemble around the PNP core
via hydrophobic interactions, with their hydrophobic tails
attached to the core and their hydrophilic heads facing the
external aqueous surrounding, resulting in the formation
of LPHNP structures [13, 15, 16, 33]. The ESE method is
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distinguished into single and double emulsification pro-
cesses. In the single ESE method, the PLGA polymeric so-
lution is added to an aqueous phase containing the lipids
to form an oil-in-water emulsion [17, 34]. In the double
ESE method, the organic phase containing the PLGA
polymer solution and lipids is emulsified with an aque-
ous buffer, and the resultant water-in-oil emulsion is
further emulsified with a stabilizer or lipid-PEG to form
a water-in-oil-in-water emulsion [15, 17]. In both
methods, once the organic solvent has evaporated, the
PNP core is formed, around which the lipids will
subsequently self-assemble, similar to the nanoprecipi-
tation method [15, 18].
Selection of the correct lipid-based surface engineering
method to use is crucial and depends on the nature of
the lipid-PLGA surface chemistry for the desired bio-
medical applications [17, 18, 35]. For instance, we
employed the single-step ESE method for gene delivery ap-
plications, and the nanoprecipitation method for the encap-
sulation and sustained release of antiproliferative agents
[13, 15]. In contrast, nanoghost-based surface engineering
cannot be achieved through single-step methods, requiring
Fig. 1 Schematic diagram explains the different methods in the lipids based surface engineering on PLGA nanoparticles
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Size(nm) Charge(mV) Application Reference
Lecithin/DSPE-PEG PLGA One step Au/QDs 50–60 NA Diagnostic/Optical imaging [32]
Chol Curcumin 203 -0.67 ± 1.23 Cancer therapy [34]
EPC, DOPE-Tf/TPGS Aromatease
Inhibitor





65 35 Cancer therapy [57]
Lecithin/DSPE-PEG Paclitaxel -
Gemcitabine
70 ± 1 -51 ± 2 Cancer therapy [58]
Lecithin/DSPE-PEG Paclitaxel 55 ± 1 NA Treatment of coronary artery
disease
[59]
DSPE-PEG docetaxel 25 -10 Cancer therapy [60]
EPC DSPE-PEG Two step siRNA 225 ± 8 - 10 Gene Delivery [61]
FA-QLCS,Chol, PEG-OQLS Paclitaxel 184 ± 7 22 ± 4 Targeted nanoparticle for cancer
therapy
[62]
Chol, DOTAP, DSPE-PEG BSA ~144 +4–6 Vaccine delivery [63]
DOPC,DOTAP, DSPE-PEG One step Sirolimus 174 ±
9.6
−14 ± 0.3 Sustained antiproliferative therapy











DOPC Sirolimus 201 ±
8.8
−24 ± 1.2
Propolis 212 ± 11 −32 ± 2.5






DOTAP (6 %) One step pDNA 209 ±
10.4
36 ± 5.4 Gene delivery [15]
DOTAP (12 %) 186 ±
7.9
49 ± 2.3
DOTAP (18 %) 163 ±
5.6
57 ± 2.5
DOTAP (24 %) 154 ±
5.2
64 ± 3.2
RBC membranes Two step Doxorubicin 70–90 -10 ± 2.7 Long circulating carrier [44]
Platelet membranes Docetaxel 113.4 ±
1.2






Cancer cell membranes NA ~110 -35 ± 5 Natural cancer targeted drug
delivery. Whole cell cancer vaccine
[64]
Monocyte membranes Doxorubicin ~150–
180





VEGF 100–150 -15 ± 1.3 Natural targeted drug delivery. Stem cell
mimetic nanocarrier
[12]
Bose et al. Biomaterials Research  (2016) 20:34 Page 4 of 9
a conventional two-step top-down approach instead [10,
12, 25, 26]. A list of LPHNP studies that employ the two-
step and single-step methods are provided in Table 1. Be-
cause of the perceived advantages of LPHNPs over other
existing hybrid systems, significant effort has been made to
understand their basic structure [36]. LPHNPs commonly
comprise a hydrophobic PNP core, a lipid monolayer or bi-
layer surrounding the core, and a lipid-PEG corona [18].
Fig. 2 depicts the advantage of different lipid surface engin-
eering on PNPs.
Applications of lipid-based surface-engineered
PLGA nanoparticles
Drug delivery
The different surface engineering methods available for
producing LPHNPs have enabled the incorporation of
an extensive range of drugs, regardless of their proper-
ties (e.g., water solubility and ionicity) [17, 37, 38].
LPHNPs have been demonstrated as a promising drug
delivery platform owing to their greater biomimetic and
biodegradable abilities, with customized targeting fea-
tures [17, 39]. The selection of lipids allows for further
customization of PNPs with desired drug delivery
features, such intracellular drug delivery or extended cir-
culation with target-specific localization [15, 31]. The
lipids on the PNP surface can act as a biocompatible
fence to control the drug-releasing kinetics and improve
the therapeutic efficacy of the drug [13]. Recently, our
research group applied this strategy to improve the anti-
proliferative efficacy of a drug in an in vitro system,
where the effects of a higher drug concentration and of
the synthetic polymeric surface of the drug-eluting stent
were reported for stent-associated thrombosis [40]. Fig. 3
show the effect of different lipids on properties of lipid-
PLGA nanoparticles (LPHNPs) for sirolimus or propolis
delivery. In Fig. 3, the schematic diagram show the
method of preparation of drug encapsulated LPHNPs and
its characterization including the morphology, release
kinetics and inhibitory effect of sirolimus or propolis
-LPHNSs on HASMCs proliferation. We demonstrated
that different lipid-based surface engineering techniques
used to produce sirolimus/propolis-loaded PNPs signifi-
cantly improved the antiproliferative efficacy of the drugs
against smooth muscle cells, while reducing the drug-
mediated cytotoxicity on endothelial cells.
Classically, PEG lipids have been employed to improve
the biodistribution and circulation half-life of PNPs, as
the PEG corona provides steric stabilization and acts as
a protective layer [41, 42]. Recently, however, PNPs engi-
neered with RBC-membrane-derived nanoghosts were
demonstrated to be better biomimetic long-circulating
nanocarriers than PEG-based PNPs [10, 43]. Moreover,
Aryal et al. demonstrated that the RBC nanoghosts on
the PNP surface could act as a diffusion barrier to better
control the drug release, as compared with PEG-based
PNPs, thereby enhancing the therapeutic efficacy of the
drug in acute myeloid leukemia cells [44].
Bare PNPs have the major drawback of nonspecific tar-
get localization, resulting in uncontrolled tissue distribu-
tion of the drug. To improve the PNPs’ site-specific
localization, various strategies have been employed [10].
Lipid-based surface engineering allows for target functio-
nalization of PNPs through either conjugation chemistry
or by conferring upon them cell-membrane-mediated
Fig. 2 Advantage and application of different lipids-surface engineering on PLGA nanoparticles. The bare PLGA nanoparticles have major drawbacks
such as hydrophobic surface, rapid phagocytic clearance and initial burst release. Cell membrane derived lipid vesicles or synthetic lipids based surface
engineering on PLGA nanoparticles prevent the fore told drawbacks and improve the clinical performance
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natural targeting capabilities [26, 45, 46]. Because target
functionalization by various conjugation chemistries has
already been reviewed by several authors, we focus here
instead on the cell-membrane-mediated approach.
Cell-membrane-derived nanoghosts have the combined
advantages of synthetic and biological features for im-
proved target specificity and drug efficacy [14, 19]. Thus,
nanoghost-based surface engineering has been actively
used to target PNPs to the diseased sites [10, 14, 19]. For
instance, Fang et al. demonstrated a significant enhance-
ment of the natural binding ability of drug-loaded PNPs
to the source cancer cells owing to the presence of adhe-
sion molecules [46, 47]. Correspondingly, platelet cells
have a natural ability to home in on injured blood vessels
as well as circulating pathogens. Thus, surface engineering
of PNPs with platelet-membrane-derived nanoghosts pro-
vides them with the natural platelet-like targeting func-
tions [26, 48]. Krishnamurthy et al. demonstrated that the
monocyte-membrane-derived nanoghost-based surface
engineering of DOX-loaded PNPs resulted in higher cyto-
toxicity in MCF-7 breast cancer cells [14, 19, 49]. In
addition, the multicompartmental nature of LPHNPs has
an advantage, in that multiple therapeutic agents can be
incorporated into the different compartments of the NPs
[17, 18, 50]. Altogether, LPHNPs have been employed
mostly for numerous drug delivery applications. The list is
quite extensive and we therefore provide only the most re-
cent applications in Table 1.
Gene delivery
Although traditional nonviral delivery systems such as
liposomes and polyethylenimine (PEI) have been con-
firmed to be effective in in vitro and in vivo models,
their clinical potential is drastically limited because of
their instability and higher cytotoxicity upon systemic
administration [51]. LPHNPs have emerged as a novel
nonviral gene delivery system owing to their improved
stability and low cytotoxicity profiles. In particular,
cationic lipid (DOTAP)-layered PNPs have numerous
advantages over lipoplex (liposome)-, polyplex (PEI)-,
and viral-based vectors, such as their large-DNA in-
corporation ability, higher transfection efficiency with
Fig. 3 Effect of different lipids on properties of lipid-PLGA nanoparticles (LPHNPs) for drug delivery application. a Schematic diagram for LPHNPs
preparation and in vitro characterization, b TEM-image of different lipids-PLGA NPs, cCLSM image of LPHNPs (Core-Shell structure), d Effect of different
lipids on sirolimus release kinetics from LPHNPs, e Effect of different lipids on propolis release kinetics from LPHNPs, f Inhibitory effect of Sirolimus-LPHNSs
on HASMCs proliferation, g Inhibitory effect of Propolis-LPHNSs on HASMCs proliferation. (Reproduced from reference.13)
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mild cytotoxicity, and feasibility for pilot-scale pro-
duction [18, 52].
As illustrated in Fig. 4, we investigated the effect of
DOTAP lipid on properties of lipid-PLGA nanoparticles
(LPHNPs) for gene delivery application. We demon-
strated the strong influence of DOTAP concentration on
the surface properties of the LPHNPs, impacting their
plasmid DNA-binding capacity, cytotoxicity, and trans-
fection efficiency in HeLa, HaCaT, HEK293T, and
HepG2 cells [11, 15]. However, the use of LPHNPs to re-
duce nonspecific protein binding has not been well in-
vestigated. At present, studies on cationic LPHNP–DNA
complexes are still in their infancy, and most investiga-
tions have focused only on nanocarrier preparation and
characterization.
Conclusions
Lipid-based surface engineering of PNPs offers
several advantages in the development of drug and
gene delivery platforms, including a broad range of
flexible strategies and ease of surface engineering,
as well as extended circulation half-life, better
target specificity, reduced cytotoxicity, and im-
proved transfection efficiency of the nanocarriers
[13, 36, 53]. Collectively, all of these features make
the lipid-based surface engineering strategies ideal
for improving the clinical performance of PNPs
[18, 24]. Although enormous progress has been
made in the area of nanoengineering, many chal-
lenges remain that potentially hinder the translation
of PNPs to the clinical arena [5, 54]. Lipid-based
surface engineering can be further optimized to
improve the clinical outcomes of PNPs in drug and
gene delivery applications [55]. Precise control of
the surface engineering with different lipids as well
as of their concentration on PNPs is critical in
gene delivery, as these factors directly influence the
efficiency of nanocarriers [15, 51].
Fig. 4 Effect of DOTAP lipid on properties of lipid-PLGA nanoparticles (LPHNPs) for gene delivery application. a Schematic diagram for LPHNPs-
DNA complex formation and transfection, b TEM-image of bare PLGA NPs, c TEM-image of LPHNPs, d Effect of DOTAP concentration on LPHNPs
surface charge, e Effect of DOTAP concentration on LPHNPs transfection efficiency in various cells (Flow cytometry analysis) and f fluorescence
microscopy. (Reproduced from reference.15)
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